Should GLP1 R agonist therapy be offered to women at high risk for breast cancer given recent data showing protective benefits?

Obesity is a key modifiable risk factor for breast cancer. While it is true that some observational studies have suggested that the use of GLP-1 RA is associated with a lower incidence of breast cancer (McDonald et al., PMID 42227662), this is an association. The authors of this study correctly poin...

Obese postmenopausal women are at higher risk for breast cancer (Xande & Giglio, PMID 40869064), and so it seems logical that weight loss will reduce risk. Reassuringly, glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications have not been shown to increase breast cancer risk (Mady et al., P...